Τίτλος:
Treatment of patients with multiple myeloma complicated by renal failure
with bortezomib-based regimens
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Renal failure is a common feature of multiple myeloma and a major
management problem. However there is limited data regarding the
reversibility of renal failure, the kinetics of serum creatinine and the
safety of novel agents such as bortezomib when administered to newly
diagnosed or relapsed/refractory patients with renal failure. Patients
and Methods. We evaluated 20 consecutive patients with newly diagnosed
or relapsed/refractory multiple myeloma and renal failure, defined as a
serum creatinine2 mg/dl. All patients received bortezomib with
dexamethasone or in combination with other agents (thalidomide,
doxorubicin or melphalan). Results. Reversal of renal failure was
documented in 40% of all patients and the median time to reversal was
17 days. Moreover 10 patients (50%) had 50% decrease in serum
creatinine and the median time to decrease was 35 days. Some decrease of
creatinine was documented in 85% of patients. The objective response
rate was 65%. Toxicities were similar to those seen in myeloma patients
without renal failure. Conclusions. Bortezomib based regimens can be
administered to myeloma patients with renal impairment and their
toxicity and efficacy are similar to those observed in patients without
renal impairment. Moreover, bortezomib-based regimens induce improvement
of serum creatinine in most patients and reversal of renal failure in
approximately one-third.
Συγγραφείς:
Roussou, Maria
Kastritis, Efstathios
Migkou, Magdalini and
Psimenou, Erasmia
Grapsa, Irini
Matsouka, Charis and
Barmparousi, Despina
Terpos, Evangelos
Dimopoulos, Meletios
Athanasios
Περιοδικό:
Leukemia & Lymphoma
Εκδότης:
TAYLOR & FRANCIS LTD LONDON
Λέξεις-κλειδιά:
myeloma; renal failure; bortezomib
DOI:
10.1080/10428190801930506
